APML03 | The Australasian Leukaemia and Lymphoma Group

DOI number	10.58109/zznv-dq19
Publisher	Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)	Australasian Leukaemia and Lymphoma Group (ALLG) Harry Iland (Royal Prince Alfred Hospital)
Date Made Available	2023
Dataset	Individual participant data (IPD) in aggregate form
Description of Dataset	Dataset includes: Data for 107 patients with newly diagnosed APL Treatment involved use of all-trans retinoic acid (ATRA) combined with idarubicin Demographic data Diagnostic data Treatment data Outcome data
Funding	Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)	Chemotherapy
ANZCTR Reference	ACTRN12607000410459
Publication(s)	Diagnosis and Molecular Monitoring of Acute Promyelocytic Leukemia Using DzyNA Reverse Transcription-PCR to Quantify PML/RARα Fusion Transcripts Molecular Monitoring of Acute Promyelocytic Leukemia by DzyNA Reverse Transcription-PCR Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Dataset Access	Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au